T1D Exchange Announces Population Health Surveillance Study of COVID-19 in Individuals with Type 1 Diabetes
09 Abril 2020 - 7:00AM
Business Wire
Results to help better understand etiology and
potential outcomes in at-risk patients and inform clinical quality
improvement activities
T1D Exchange today announced the launch of a population health
surveillance study of individuals with type 1 diabetes (T1D) who
are suspected or confirmed to have contracted Coronavirus Disease
2019 (COVID-19). The results of the study will be used to better
understand the etiology and potential outcomes in COVID-19 patients
and inform future clinical quality improvement activities to better
respond to the global pandemic.
The ongoing outbreak of the novel respiratory disease, COVID-19,
has become a significant threat to global health and individuals
with pre-existing medical conditions, such as diabetes, appear to
be more vulnerable to becoming severely ill. According to recent
data from the American Diabetes Association, individuals with
uncontrolled diabetes are more likely to have worse outcomes and in
particular, for individuals with T1D, an infection could lead to
severe adverse outcomes such as diabetic ketoacidosis (DKA) and
other serious complications, or possibly even death.
“T1D Exchange believes in the power of collecting and
translating real-world experiences into actionable solutions to
improve care and this is underscored in the launch of this
important study,” said David Walton, CEO of T1D Exchange. “We
believe this is the first study that investigates the prevalence,
presentation and outcomes of COVID-19 specifically on those living
with type 1 diabetes, and the findings will be critical to inform
the future of treatment and care.”
The study is starting with 35 diabetes clinics, including the 14
member clinics of T1D Exchange’s Quality Improvement Collaborative
(QIC), all of whom have already signed up to share ongoing COVID-19
data. Clinics do not need to be members of the QI Collaborative
(QIC) to take part in this study. For clinics interested in joining
the study please visit: www.t1dexchange.org/covid19 or contact us
at QI@tidexchange.org.
Lead authors of the study are Dr. Osagie Ebekozien, Vice
President, Population Health and Quality Improvement, at T1D
Exchange, Dr. Guy Todd Alonso, Barbara Davis Center for Diabetes,
Children’s Hospital Colorado, and Dr. Mary Pat Gallagher, Pediatric
Diabetes Center, Hassenfeld Children’s Hospital at NYU Langone
Health.
“We are encouraged by the number of clinics that have already
signed up to be part of this study and we expect this number to
grow as we all work together to redefine best practices and improve
the quality of care,” said Dr. Ebekozien at T1D Exchange. “We are
addressing a missing but critical gap on the clinical impact of
COVID-19 in individuals with T1D, and understanding and cataloging
clinical characteristics of those who may have contracted COVID-19
will be essential for preparing best practices and management
strategies moving forward.”
Study sponsorship opportunities are still available and
organizations looking to sponsor the study or more information,
please contact Charles Iacono at ciacono@T1DExchange.org.
Questions about the T1D COVID 19 study or how to join the T1D
Exchange QI Collaborative can be directed to
QI@T1DExchange.org.
About Type 1 Diabetes T1D is an autoimmune condition in
which an individual’s body is unable to produce insulin. The
disease affects approximately 1.6 million people in the U.S., with
an estimated 40,000 new people diagnosed each year. Neither
preventable nor curable, living with T1D requires constant
monitoring of blood sugar levels and unparalleled attention to care
to avoid the acute dangers caused by hypoglycemia, in which blood
sugar drops too low, or the long term implications of
hyperglycemia, in which blood sugar rises too high.
About the Quality Improvement Collaborative The Quality
Improvement Collaborative (QIC) brings together 14 clinics,
situated across the US and treating more than 28,000 individuals
with type 1 diabetes. The QIC has achieved unprecedented success
because it relies on an embedded and systemic approach: individual
providers are empowered to identify areas of unmet need within
their clinic. They make small changes in care that scale up through
the QIC to create best practices, which are then shared among and
implemented by members at other clinics.
The T1D Exchange Quality Improvement Collaborative is funded by
The Leona M. and Harry B. Helmsley Charitable Trust.
About T1D Exchange T1D Exchange is a leading provider of
real-world evidence, dedicated to improving care for people
affected by T1D. T1D Exchange actively supports quality improvement
and innovation through its Quality Improvement Collaborative,
online patient registry, and data-centric research services. It
plays an active role in creating real-world impact with this
integrated data by providing clinicians, researchers, industry
partners and advocates with the resources and services they need
for better decision support and population health management.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200409005166/en/
For Media: Lauren Arnold Vice President larnold@macbiocom.com
781-235-3060